Abstract 5129
Background
Describe adherence patterns to the medical control processes derived from belonging to a CG situation in a sample of patients in CG situation for hereditary breast and ovarian cancer (CMOH), and its consequences with Psychological Wellbeing.
Methods
Descriptive cross-sectional descriptive study. Participants: Women carriers of high penetrance genes for breast and ovarian cancer (BRCA1 / 2), during the months of July 2012 to May 2014 who continue to control the Hereditary Cancer program of the Català Oncología Institute. 176 women. For the adhesion assessment, 3 asdoca questions were asked, based on recommendations and guidelines, the scale of the psychological well-being (BP) of Ryff was used, validated in the Spanish population.
Results
Regarding breast autoexploration, 58.6% of the patients did not follow the correct follow-up (either by hypervigilance or hypovigilance). Regarding the follow-ups in mammographic controls, 51.4% of the patients do the correct follow-up. When analyzing the relationship between breast self-exploration and the dimensions of psychological well-being, no statistically significant differences were found in any case, the same happens with mammographic controls Regarding the follow-up by MRI, 51.4% of the patients follow the correct one. A relationship is found in the dimension of Autonomy and Purpose in life.
Conclusions
The literature reports that there are well-defined and structured medical treatment protocols that allow monitoring of the carrier patients and that these are understandable to them with the final objective that patients have strategies to manage the situation without uncertainty (Ringwald et al., 2016). One possible explanation is that patients do not fully understand the protocols or that there are other personality variables that are modulating this aspect, such as a passive coping style or a high perception of risk (Den Heijer et al., 2013; Gopie et al., 2012). Conclusions Our population, approximately 50% of patients do not adhere to the proposed follow-up measures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Melinda Gonzalez Concepcion.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract